|
|
||||||||
1 Centro de Investigación y de Estudios Avanzados del Institúto Politécnico Nacional, Mexico DF 07300; 2 Department of Pharmacology, New York Medical College, Valhalla, New York 10595; and 3 College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas 77004
We examined the rat
proximal tubule (PT) response to endothelin-1 (ET-1) in terms of
20-hydroxyeicosatetraenoic acid (HETE) dependency. Arachidonic acid
(AA) (1 µM) decreased ouabain-sensitive 86Rb uptake from
2.1 ± 0.1 to 0.3 ± 0.08 ng Rb · 10 µg
protein
1 · 2 min
1
(P < 0.05); 20-HETE (1 µM) had similar effects.
Dibromododecenoic acid (DBDD) (2 µM), an inhibitor of
-hydroxylase, abolished the inhibitory action of AA on
86Rb uptake whereas the PT response to 20-HETE was
unaffected. ET-1 at 0.1, 1, 10, and 100 nM reduced 86Rb
uptake from 2.8 ± 0.3 in control PTs to 2.4 ± 0.2, 1.7 ± 0.1, 0.67 ± 0.08, and 0.1 ± 0.03 ng Rb · 10 µg
protein
1 · 2 min
1, respectively.
DBDD (2 µM) abolished the inhibitory effect of ET-1 on
86Rb uptake as did BMS182874 (1 µM), an
ETA-selective receptor antagonist. ET-1 (100 nM)
significantly increased PT 20-HETE release by ~50%, an
effect prevented by DBDD.
N
-nitro-L-arginine-methyl
ester (L-NAME), given for 4 days to inhibit nitric oxide
synthase (NOS), increased arterial pressure from 92 ± 12 to
140 ± 8 mmHg and increased endogenous release of 20-HETE from
isolated PTs (measured by gas chromatography/mass spectrometry). In
L-NAME-treated PTs, but not in control PTs, 0.1 µM AA
inhibited ouabain-sensitive 86Rb uptake by >40%; the
response to AA was attenuated by DBDD. We conclude that, in the PTs,
1) 20-HETE is a second messenger for ET-1 and 2)
conversion of AA to 20-HETE is augmented when NOS is inhibited.
20-hydroxyeicosatetraenoic acid; arachidonic acid metabolites; endothelin-1; nitric oxide
This article has been cited by other articles:
![]() |
P. Minuz, H. Jiang, C. Fava, L. Turolo, S. Tacconelli, M. Ricci, P. Patrignani, A. Morganti, A. Lechi, and J. C. McGiff Altered Release of Cytochrome P450 Metabolites of Arachidonic Acid in Renovascular Disease Hypertension, May 1, 2008; 51(5): 1379 - 1385. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yu, B. Lopez, E. A. Dos Santos, J. R. Falck, and R. J. Roman Effects of 20-HETE on Na+ transport and Na+-K+-ATPase activity in the thick ascending loop of Henle Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2007; 292(6): R2400 - R2405. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Williams, X. Zhao, M. H. Wang, J. D. Imig, and D. M. Pollock Peroxisome Proliferator-Activated Receptor-{alpha} Activation Reduces Salt-Dependent Hypertension During Chronic Endothelin B Receptor Blockade Hypertension, August 1, 2005; 46(2): 366 - 371. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Lee, C. S. Landon, S. J. Nazian, and J. R. Dietz Cytochrome P-450 metabolites in endothelin-stimulated cardiac hormone secretion Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2004; 286(5): R888 - R893. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |